NEWS & EVENTS

Latest news and upcoming events

Ysios Capital ESG Report
20 Nov 2024

Ysios Capital ESG Report

Upcoming events

  • Brain Innovation Days
    13 - 14 November 2024,
    Brussels

    download

  • Congreso CIBER
    27 - 24 November 2024
    Valencia

    download

  • Bio-Neuroscience
    25 - 27 February 2025
    Amsterdam

    download

  • 18th Annual European Life Sciences CEO Forum
    26 - 27 February 2025
    Zurich

    download
Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First- in-class ADC Pipeline<
25 Nov 2024

Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First- in-class ADC Pipeline

Proceeds will be used to support the advancement of multiple first-in-class ADC programs into the clinic and through clinical proof of concept
AELIX’s HTI HIV Vaccine Investigational Assets Acquired by Gilead Sciences<
25 Nov 2024

AELIX’s HTI HIV Vaccine Investigational Assets Acquired by Gilead Sciences

The HTI vaccines have shown promising results in phase 1 and phase 2 clinical trials
Ysios Capital ESG Report<
20 Nov 2024

Ysios Capital ESG Report

A milestone reflecting the firm’s deep commitment to responsible and sustainable investment.
Xeltis announces FDA Breakthrough Device Designation for aXessTM and first patient treated in US pivotal trial<
14 Nov 2024

Xeltis announces FDA Breakthrough Device Designation for aXessTM and first patient treated in US pivotal trial

Designation recognizes aXess has the potential of providing a more effective vascular access option for dialysis patients, bringing significant advantages over current therapies
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights<
12 Nov 2024

Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights

Strong Cash Position Expected to Support Operations into 2H 2026
VarmX announces appointment of John Glasspool as CEO<
12 Nov 2024

VarmX announces appointment of John Glasspool as CEO

Leadership team fully strengthened to drive next phase of development
Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update<
11 Nov 2024

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Two pivotal trials fully enrolled and on track to deliver topline data during the first half of 2025.
Xeltis expands leadership team with appointment of Luc Verhees as Vice President of Clinical Business Development<
05 Nov 2024

Xeltis expands leadership team with appointment of Luc Verhees as Vice President of Clinical Business Development

Brings over 30 years of experience in cardiovascular clinical research, business development, training, education, and medical affairs
Memo Therapeutics AG Appoints Frits van Alphen, MD as Chief Development Officer<
04 Nov 2024

Memo Therapeutics AG Appoints Frits van Alphen, MD as Chief Development Officer

Frits is an industry veteran with a proven track record in nephrology drug development
Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant Patients<
01 Nov 2024

Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant Patients

Topline data expected in mid-2025

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Для комфортной игры важна надежное и проверенное casino. Joycasino официальный сайт предлагает пользователям обширный выбор слотов, приветственные бонусы и качественный сервис 24/7 для увлекательного и безопасного времяпрепровождения.